Empagliflozin Relaxes Resistance Mesenteric Arteries by Stimulating Multiple Smooth Muscle Cell Voltage-Gated K+ (KV) Channels
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Empagliflozin Relaxes Resistance Mesenteric Arteries by Stimulating Multiple Smooth Muscle Cell Voltage-Gated K+ (KV) Channels
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 19, Pages 10842
Publisher
MDPI AG
Online
2021-10-09
DOI
10.3390/ijms221910842
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials
- (2021) Yao Hao Teo et al. Journal of the American Heart Association
- Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure
- (2021) Xuan Li et al. Journal of the American Heart Association
- SGLT2 Inhibitors in Cardiovascular Medicine
- (2021) Fahimeh Varzideh et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure
- (2021) Michael Böhm et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
- (2021) Julie Kolwelter et al. ESC Heart Failure
- Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series
- (2020) Matthew Griffin et al. ESC Heart Failure
- Correction: Intravascular flow stimulates PKD2 (polycystin-2) channels in endothelial cells to reduce blood pressure
- (2020) Charles E MacKay et al. eLife
- Empagliflozin dilates the rabbit aorta by activating PKG and voltage-dependent K+ channels
- (2020) Mi Seon Seo et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways
- (2020) Raquibul Hasan et al. Scientific Reports
- Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK–Akt–eNOS pathway in the isoprenaline-induced oxidative stress model
- (2020) Raquibul Hasan et al. Scientific Reports
- Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction
- (2020) Rio P. Juni et al. KIDNEY INTERNATIONAL
- How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
- (2019) Agnes Bosch et al. Cardiovascular Diabetology
- Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation
- (2019) Alex Ali Sayour et al. Journal of Translational Medicine
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Hypertension and type 2 diabetes: lights and shadows about causality
- (2019) GianLuca Colussi et al. JOURNAL OF HUMAN HYPERTENSION
- Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats
- (2019) Alana Aragón-Herrera et al. BIOCHEMICAL PHARMACOLOGY
- SUMO1 modification of PKD2 channels regulates arterial contractility
- (2019) Raquibul Hasan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Diabetes and Hypertension: Clinical Update
- (2018) Darshan Khangura et al. AMERICAN JOURNAL OF HYPERTENSION
- Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
- (2018) Sarayut Lahnwong et al. Cardiovascular Diabetology
- The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels
- (2018) Hongliang Li et al. LIFE SCIENCES
- KV channel trafficking and control of vascular tone
- (2018) Raquibul Hasan et al. MICROCIRCULATION
- KV channels and the regulation of vascular smooth muscle tone
- (2018) William F. Jackson MICROCIRCULATION
- Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
- (2018) Νarjes Nasiri-Ansari et al. Cardiovascular Diabetology
- Arterial smooth muscle cell PKD2 (TRPP1) channels regulate systemic blood pressure
- (2018) Simon Bulley et al. eLife
- Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese
- (2017) Yukako Tatsumi et al. HYPERTENSION RESEARCH
- XE991 and Linopirdine Are State-Dependent Inhibitors for Kv7/KCNQ Channels that Favor Activated Single Subunits
- (2017) Derek L Greene et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
- (2017) Sebastian Steven et al. Redox Biology
- The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet
- (2016) Ji Hye Han et al. DIABETOLOGIA
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
- (2016) Michael A Weber et al. Lancet Diabetes & Endocrinology
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- (2015) R. Chilton et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intravascular pressure enhances the abundance of functional Kv1.5 channels at the surface of arterial smooth muscle cells
- (2015) Michael W. Kidd et al. Science Signaling
- Intravascular pressure enhances the abundance of functional Kv1.5 channels at the surface of arterial smooth muscle cells
- (2015) Michael W. Kidd et al. Science Signaling
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
- (2014) Ilkka Tikkanen et al. DIABETES CARE
- Empagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
- (2014) Lesley J. Scott DRUGS
- Paxilline inhibits BK channels by an almost exclusively closed-channel block mechanism
- (2014) Yu Zhou et al. JOURNAL OF GENERAL PHYSIOLOGY
- Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
- (2014) Raymond V. Oliva et al. Journal of the American Society of Hypertension
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2013) EUROPEAN HEART JOURNAL
- cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action
- (2010) S. H. Francis et al. PHARMACOLOGICAL REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search